CXCL12 and acute respiratory distress syndrome: The observation that engineered CXCL121 outperformed ubiquitin and wild-type CXCL12 in its overall pharmacodynamic properties implies that the development of new engineered protein therapeutics with improved pharmacological properties for ARDS is possible.